Pms60 - Clinical and Economic "Real World” Analysis of the Switching From Remicade (Infliximabe) by Remsima (Infliximab Biossimilar) of Planserv Patients With Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis.
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1774
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV